Metabolic Responses to Reductive Stress

Wusheng Xiao and Joseph Loscalzo

Abstract

Significance: Reducing equivalents (NAD(P)H and glutathione [GSH]) are essential for maintaining cellular redox homeostasis and for modulating cellular metabolism. Reductive stress induced by excessive levels of reduced NAD\(^+\) (NADH), reduced NADP\(^+\) (NADPH), and GSH is as harmful as oxidative stress and is implicated in many pathological processes.

Recent Advances: Reductive stress broadens our view of the importance of cellular redox homeostasis and the influences of an imbalanced redox niche on biological functions, including cell metabolism.

Critical Issues: The distribution of cellular NAD(H), NADP(H), and GSH/GSSG is highly compartmentalized. Understanding how cells coordinate different pools of redox couples under unstressed and stressed conditions is critical for a comprehensive view of redox homeostasis and stress. It is also critical to explore the underlying mechanisms of reductive stress and its biological consequences, including effects on energy metabolism.

Future Directions: Future studies are needed to investigate how reductive stress affects cell metabolism and how cells adapt their metabolism to reductive stress. Whether or not NADH shuttles and mitochondrial nicotinamide nucleotide transhydrogenase enzyme can regulate hypoxia-induced reductive stress is also a worthy pursuit. Developing strategies (e.g., antireductant approaches) to counteract reductive stress and its related adverse biological consequences also requires extensive future efforts.

Keywords: NAD(H), NADP(H), GSH/GSSG, reductive stress, cellular metabolism, redox

Introduction

Mammalian cells depend on a series of oxidation and reduction (redox) reactions to generate energy (e.g., ATP) and to synthesize essential cellular components (e.g., nucleic acids) from nutrients in support of their biological functions. In a redox reaction, electrons flow from reducing agents (reductants) to oxidizing agents (oxidants). Cellular redox couples, mainly nicotinamide adenine dinucleotide (NAD\(^+\))/reduced NAD\(^+\) (NADH), phosphorylated NAD\(^+\) (NADP\(^+\))/reduced NADP\(^+\) (NADPH), and reduced glutathione (GSH)/GSSG, are responsible for the bulk of cellular electron transfer (88, 106). These redox couples serve as cofactors or substrates for enzymatic or nonenzymatic neutralization of reactive oxygen species (ROS) to sustain a relatively reducing environment in cells.

Importantly, these redox couples also link the cellular redox environment with cellular energetics. For instance, NAD\(^+\) serves as an electron sink to support glycolysis; NADH provides electrons for mitochondrial oxidative phosphorylation (OXPHOS); and NADPH is a major electron source for reductive biosynthesis of fatty acids and nucleic acids (112, 115). Given that these reducing equivalents are indispensable for cellular redox homeostasis and energy metabolism, an imbalance of the redox state of these molecules is implicated in a variety of pathological conditions, such as cardiovascular diseases, neurodegenerative diseases, cancer, and aging (10, 115).

In this review, we first introduce the cellular redox network and redox stress, and then delineate the metabolic sources and cellular distribution of the NAD\(^+\)/NADH, NADP\(^+\)/NADPH, and GSH/GSSG redox couples. This information is followed by an explanation of how perturbations...
in these ratios lead to reductive stress. Finally, we discuss metabolic responses to reductive stress and their impact on cell function.

**Cellular Redox Network and Redox Stress**

*Redox network in mammalian cells*

The cellular redox niche is balanced by pro-oxidants and antioxidants. Cellular pro-oxidants include ROS (e.g., superoxide anion \([\text{O}_2^-]\) and hydrogen peroxide \([\text{H}_2\text{O}_2]\)), reactive nitrogen species (RNS; e.g., nitric oxide \([\text{NO}^\bullet]\)), and their derivatives (e.g., peroxynitrite \([\text{ONOO}^-]\)), which are primarily produced by enzymes, such as NAD(P)H oxidases (NOXs) and uncoupled nitric oxide synthases, or by the mitochondrial electron transport chain as functional by-products (30, 87). To counteract these oxidants, cells have developed antioxidant systems, including antioxidant enzymes, for example, superoxide dismutases (SOD1–3), catalase, glutathione peroxidases (GPx1–8), thioredoxins (Trx1–2), and peroxiredoxins (Prx1–6); and nonenzymatic small molecules, for example, GSH, \(\alpha\)-tocopherol, and ascorbate (7, 30, 87) (Fig. 1).

Of note, the production of cellular oxidants is compartment specific, but their targets can be local or/and remote from the source compartment. For example, mitochondria-generated \(\text{H}_2\text{O}_2\) can function as a signaling molecule in mitochondria (local) or/and in cytosol (remote) (26). In the vasculature, endothelial cell-derived NO\(^\bullet\) can diffuse from the endothelium to adjacent smooth muscle cells leading to vasodilation (22). Unlike oxidants, antioxidant enzymes exercise their functions depending on their specific subcellular localization. For example, manganese SOD (SOD2), a mitochondrial matrix-localized enzyme, can only convert \(\text{O}_2^-\) into \(\text{H}_2\text{O}_2\) in mitochondria, where \(\text{H}_2\text{O}_2\) is subsequently reduced to water by mitochondrial peroxidases (such as catalase, GPx1, GPx4, and Prx2).

The GSH/GSSG couple and the NADP\(^+\)/NADPH couple play crucial roles in the two-electron reduction of peroxides. GSH is a cosubstrate of GPxs for \(\text{H}_2\text{O}_2\) removal. In this context, two molecules of GSH donate two electrons to reduce \(\text{H}_2\text{O}_2\) to water and themselves are oxidized to GSSG, which is then recycled back to GSH by glutathione reductase (GR) using NADPH as an electron donor (7, 8) (Fig. 1). It is interesting to note that glutaredoxins (Grx1–2) also utilize GSH to reduce protein intra/inter-disulfides (PS\(_2\) or protein-glutathione disulfide [PSSG]) into protein sulfhydryl groups (-SH) (7, 8) (Fig. 1). In addition to GR, NADPH is also an

![Cellular redox network](image_url)
indispensable cofactor for thioredoxin reductases (TRs). Likewise, NADPH provides two electrons for TRs to reduce oxidized Trx (Trx-S2) to its active dithiol form Trx-(SH)2. The reduced form Trx-(SH)2 serves as an electron source for regeneration of Prxs, which reduce H2O2 and other organic hydroperoxides to water and alcohols, respectively (7, 8) (Fig. 1). Notably, intracellular total Trx content was estimated to be 1–10 μM in bovine tissues (34), which is 2–3 orders of magnitude lower than total GSH levels (mM range).

**Redox stress**

Under physiological conditions, cellular pro-oxidants are maintained at steady-state levels required for many biological processes, such as cell signaling, proliferation, and differentiation (30, 87). However, when the balance between pro-oxidants and antioxidants is adversely perturbed, redox stress, including oxidative stress and reductive stress, occurs (Fig. 2).

The concept of oxidative stress was first introduced by Paniker et al. in 1970 in studies of the GSH/GSSG couple in H2O2-stimulated normal and GR-deficient human erythrocytes (74). This term is now defined as the imbalance between cellular pro-oxidant levels and antioxidant capacity in favor of the former (30, 52, 87), implying that an excess in oxidant cellular pro-oxidant levels and antioxidant capacity in favor of the latter (30, 52, 87). By contrast, reductive stress is an excess accumulation of reducing equivalents (specifically NADH, NADPH, and GSH), exceeding the capacity of endogenous oxidoreductases.

![FIG. 2. Redox stress. The NADH/NAD⁺, NADPH/NADP⁺, and GSH/GSSG redox couples are the major cellular redox buffers. Under unstressed conditions, these three redox couples have adequate capacity to maintain redox homeostasis, termed basal ReBC (X-axis; green box under red line). When cellular ROS levels increase (Left Y-axis; red line), these redox buffers are also able to respond by elevating basal ReBC to a certain level, termed the compensatory ReBC (X-axis; gray area under red line). Under both circumstances, cellular ROS levels are maintained at physiological levels to ensure normal biological function, such as signaling molecule adequacy (Right Y-axis; blue line). However, when this compensatory response continues beyond a certain threshold at which the maximal ReBC is exceeded by cellular reducing of ROS levels (X-axis, black triangle), reductive stress can occur (red line). By contrast, oxidative stress occurs when cellular ReBC decreases (X-axis, black triangle), or cellular oxidation of ROS production is overwhelming. Both reductive stress and oxidative stress (collectively named as redox stress) can promote ROS production leading to oxidative damages to macromolecules and perturbations of cellular functions. NAD⁺, nicotinamide adenine dinucleotide; NADH, reduced NAD⁺; NADP⁺, phosphorylated NAD⁺; ReBC, redox buffer capacity; ROS, reactive oxygen species.](image-url)
protein response and ER stress (60). In line with this concept, we and others showed that reductive stress perturbs protein disulfide formation leading to ER stress in yeast and intracellular retention of membrane proteins in human cells (32, 60, 100, 113). Furthermore, mice with cardiac-specific overexpression of mutated human aB-crystallin (hR120GCryAB) displayed increased in GSH levels and in activities of GR, glucose-6-phosphate dehydrogenase (G6PD), catalase, and GPx (indicative of reductive stress), which led to the development of cardiac hypertrophy and heart failure in these mice (77, 78). Elevated cytosolic NADH/NAD\(^+\) and its resulting reductive stress were observed in early diabetic animals owing to increased oxidation of substrates (e.g., sorbitol, nonesterified fatty acids, and glucuronic acid pathway metabolites), which was coupled with the reduction of NAD\(^+\) to NADH (38). Thus, reductive stress is deleterious to cells and has been linked to many pathological conditions, including cardiovascular diseases and diabetes mellitus (31, 51, 105).

### Metabolic Sources of the NAD(H) and NAD(P)H Couples

**NAD\(^+\)**, a key cofactor for many enzymes including metabolic enzymes, is critical for various biological processes (106). Mammalian cells can synthesize NAD\(^+\) *de novo* from its precursors and recycle NAD\(^+\) from NADH. Depending on availability of its precursors, NAD\(^+\) can be synthesized *via* three pathways: the *de novo* pathway using tryptophan as a precursor, the *Preiss-Handler* pathway using nicotinic acid as a precursor, and the salvage pathway using nicotinamide (NAM) and nicotinamide riboside (NR) as precursors (106). NAD\(^+\) can be phosphorylated to NADP\(^+\) *via* NAD\(^+\) kinases (NADKs); the oxidized forms of NAD\(^+\) and NADP\(^+\) can be reduced to NADH and NADPH by their corresponding dehydrogenases (106). We and others have extensively reviewed the enzymatic steps and the regulatory factors of all three NAD\(^+\) biosynthetic pathways (106, 112, 114). In this review, we primarily focus on the interconversion of NAD(H) and NADP(H) *via* metabolic enzymes.

**Metabolic sources of the NAD(H) and NAD(P)H couples**

The interconversion of NAD(P)\(^+\) and NAD(P)H is mediated by metabolic enzymes involved in glycolysis, the pentose phosphate pathway (PPP), and the tricarboxylic acid (TCA) cycle (Figs. 3 and 4). Glycolysis and the TCA cycle are the two major sources of cytosolic and mitochondrial NAD(H), respectively (Fig. 3). In the cytosol, the interconversion of NAD\(^+\) and NADH is catalyzed by two enzymes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH) (56, 106). GAPDH catalyzes the reversible conversion of glyceraldehyde-3-phosphate (G-3-P) to 1,3-bisphosphoglycerate in conjunction with the corresponding interconversion of the NAD\(^+\)/NADH couple. LDH reduces pyruvate to lactate coupled with the oxidization of NADH to NAD\(^+\) in glycolysis. Of note, LDH can also catalyze the reverse reaction by reducing NAD\(^+\) to NADH and oxidizing lactate to pyruvate when lactate is utilized as a fuel source for the TCA cycle (37, 94). Additional sources of cytosolic NAD(H) include the alcohol dehydrogenases (ADHs) and aldehyde dehydrogenases (11).

In the mitochondria, eight molecules of NADH can be generated by per molecule of glucose through the TCA cycle under well-oxygenated conditions (112). The pyruvate dehydrogenase (PDH) complex reduces NAD\(^+\) to NADH in conjunction with decarboxylating pyruvate to acetyl-CoA. The latter enters the TCA cycle, where NADH is produced by

---

### Table 1. Standard Reduction Potentials (E°) of Representative Redox Couples

| Redox couples | E°/mV at 25°C | Reduction types | Oxidizing ability |
|---------------|---------------|-----------------|-------------------|
| NAD\(^+\), H\(^+\)/NADH | -316 | Two-electron reduction | Low |
| NADP\(^+\), H\(^+\)/NADPH | -315 | | |
| GSSG, 2H\(^+\)/GSH | -320 | | |
| Trx-S\(_2\), 2H\(^+\)/Trx(SH)\(_2\) | -230 | | |
| Cys-S-S-Cys, 2H\(^+\)/2Cys-SH | -219 | | |
| FMN, 2H\(^+\)/FMNH\(_2\) | -219 | | |
| FAD, 2H\(^+\)/FADH\(_2\) | -219 | | |
| Grx-S\(_2\), 2H\(^+\)/Grx(SH)\(_2\) | -218 | | |
| Acetaldehyde, 2H\(^+\)/alcohol | -197 | | |
| Pyruvate, 2H\(^+\)/lactate | -183 | | |
| Oxaloacetate, 2H\(^+\)/malate | -166 | | |
| 2H\(_2\)O\(_2\)+2e\(^-\)/H\(_2\)(g), 2H\(_2\)O | 0 | | |
| Ubiquinone, 2H\(^+\)/ubihydroquinone | +84 | | |
| Ascorbate\(^+\)+, H\(^+\)/ascorbate | +282 | | |
| O\(_2\), 2H\(^+\)/H\(_2\)O\(_2\) | +300 | | |
| H\(_2\)O\(_2\), 2H\(^+\)/H\(_2\)O, HO\(^+\) | +320 | | |
| \(\alpha\)Tocopheroxyl\(^+\), H\(^+\)/vitamin E | +500 | | |
| RS\(^+\)/RS\(_2\) (thiolate) | +920 | | |
| O\(_2\)^\(-\), 2H\(^+\)/H\(_2\)O\(_2\) | +940 | | |
| ROO\(^+\), H\(^+\)/ROOH (alkylperoxyl radical) | +1000 | | |
| RO\(^+\), H\(^+\)/ROH (alkylalcoholic radical) | +1600 | | |
| HO\(^+\), H\(^+\)/H\(_2\)O | +2310 | | |

Adapted from Schafer and Buettner (89) with permission.

GSH, glutathione; Grx, glutaredoxin; GSSG, GSH disulfide; H\(_2\)O\(_2\), hydrogen peroxide; NAD\(^+\), nicotinamide adenine dinucleotide; NADH, reduced NAD\(^+\); NADP\(^+\), phosphorylated NAD\(^+\); NADPH, reduced NADP\(^+\); O\(_2\)^\(-\), superoxide anion; Trx, thioredoxin.
isocitrate dehydrogenase 3 (IDH3), \(\alpha\)-ketoglutarate dehydrogenase (KGDH), and malate dehydrogenase 2 (MDH2) (56, 106) (Fig. 3). Moreover, NAD\(^+\)-linked malic enzyme (ME2) and glutamate dehydrogenases (GLUD1–2) also contribute to the mitochondrial NADH pool (81, 106) (Fig. 3).

Cytosolic NADPH is primarily generated from the PPP by G6PD and 6-phosphogluconate dehydrogenase (6PGD) (56, 106, 112). G6PD converts glucose-6-phosphate (G-6-P) to 6-phosphogluconate, which is further metabolized into ribulose-5-phosphate by 6PGD. Both reactions are coupled to the reduction of NADP\(^+\) to NADPH (Fig. 4). Of note, ribulose-5-phosphate and its derivative ribose-5-phosphate (R-5-P) can be converted into fructose-6-phosphate (F-6-P) and G-3-P by transaldolase/transketolase through a series of nonoxidative reactions and thereby be diverted into glycolysis (56).

In addition, other enzymes also contribute to the cytosolic NADPH pool, such as IDHs, MEs, methylene-tetrahydrofolate dehydrogenases (MTHFDs), and 10-formyl-tetrahydrofolate dehydrogenases (FTHFDHs) (56, 111), all of which have both cytosolic and mitochondrial isozymes. For example, cytosolic IDH (IDH1) and mitochondrial IDH2 catalyze the oxidation of isocitrate to \(\alpha\)-ketoglutarate (\(\alpha\)-KG) and the reduction of NADP\(^+\) to NADPH. Cytosolic malic enzyme (ME) 1 decarboxylates malate to pyruvate coupled with the reduction of NADP\(^+\) to NADPH. Moreover, two enzymes in folate metabolism also generate NADPH; cytosolic MTHFD (MTHFD1) catalyzes 5,10-methylene-tetrahydrofolate (5,10-methylene-THF) to 5,10-methyl-THF; and cytosolic FTHFDH catalyzes the recycling of 10-formyl-THF to THF (111).

Mitochondrial NADPH can be produced by the mitochondrial enzymes IDH2, ME3, MTHFD2, and FTHFDH using the same reaction as their corresponding cytosolic isozymes (56, 111) (Fig. 4). NADP\(^+\)-dependent GLUDs can also generate NADPH through the conversion of glutamate to \(\alpha\)-KG (81). Of note, another significant source of mitochondrial NADPH is nicotinamide nucleotide transhydrogenase (NNT). NNT resides in the mitochondrial inner membrane and obtains electrons from NADH to reduce NADP\(^+\) into NADPH utilizing the proton gradient across mitochondrial inner membrane as a driving force: NADH + NADP\(^+\) \rightleftharpoons NAD\(^+\) + NADPH (35, 84). It has been estimated that IDH2, NNT, and ME3 contributed 70%, 22%, and 8%, respectively, of mitochondrial NADPH production in cardiac tissue of C57BL/6N mice (69).

**Compartmental distribution of cellular NAD(H) and NADP(H)**

The intracellular distribution of NAD(H) and NADP(H) is highly compartmentalized owing to specific localization of their biosynthetic enzymes and membrane permeability to these dinucleotides (106). For example, mitochondrial nicotinamide mononucleotide adenyllytransferase and mitochondrial NADK support NAD\(^+\) and NADP\(^+\) synthesis, respectively, in this organelle (10, 71, 118). While NAD(P)\(^+\) can freely pass through the nuclear membrane, none of these dinucleotides can diffuse across the mitochondrial inner membrane (35, 114). Of note, different compartmental NAD(H) and NADP(H) pools differentially respond to

![FIG. 3. Metabolic sources of NAD(H).](image-url)
exogenous stimuli. Typically, cytoplasmic and nuclear NAD(H) pools are more sensitive to changes in redox stress than the mitochondrial NAD(H) pool, which is stably maintained and required for cell survival under redox insults (108, 120).

Although cytosolic, nuclear, and mitochondrial NAD(H) and NAD(P)H pools often function in their respective compartments, these compartmental dinucleotide pools also exchange via shuttle mechanisms to maintain the overall cellular redox environment and redox-dependent functions. Cytosolic NADH can freely diffuse through the porous mitochondrial outer membrane; however, it is unable to pass through the mitochondrial inner membrane (10, 76, 112). To circumvent this limitation, cells developed two NADH shuttles: the malate/aspartate shuttle and the glycerol-3-phosphate shuttle (35, 65, 106).

In the first shuttle, cytosolic NADH is oxidized to NAD$^+$ by MDH1 in conjunction with the reduction of oxaloacetate (OAA) to malate; whereas in the mitochondria, NAD$^+$ is reduced to NADH by MDH2 coupled with the oxidation of malate back to OAA in the TCA cycle (106). This shuttle also requires two transporters, the α-KG/malate antiporter (encoded by SLC25A11 gene), which transfers cytosolic malate into the mitochondrial matrix; and the aspartate/glutamate antiporter (encoded by SLC25A13 gene), which transfers mitochondrial aspartate into the cytosol (106). Unlike the malate/aspartate shuttle, the glycerol-3-phosphate shuttle is irreversible and needs only one enzyme, glycerol-3-phosphate dehydrogenase (GPDH) (65). Cytosolic GPDH oxidizes NADH to NAD$^+$ in conjunction with the reduction of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate, whereas mitochondrial GPDH catalyzes the reverse reaction that oxidizes glycerol-3-phosphate into DHAP and reduces FAD into FADH$_2$. Therefore, such shuttle mechanisms enable cells to maintain adequate NAD$^+$ in the cytosol in support of glycolysis and sufficient NADH in the mitochondria in support of OXPHOS.

Like NADH, NADP(H) cannot diffuse across the mitochondrial inner membrane (10, 76, 112). The exchange of cytosolic and mitochondrial NADP(H) pools is, therefore,
carried out by the isocitrate-α-KG shuttle through IDH1 and IDH2 isozymes (35, 73, 106) (Fig. 4). Cytosolic IDH1 and mitochondrial IDH2 catalyze the reversible interconversion between isocitrate and α-KG in conjunction with the interconversion of NADP⁺ and NADPH (106). This shuttle also requires two carrier proteins, the citrate carrier protein (encoded by SLC25A1 gene), which exports mitochondrial iso-
citrate into the cytosol in exchange for malate; and the α-KG/ malate antipporter, which is the same carrier as in the malate/ aspartate shuttle (106). Thus, the isocitrate-α-KG shuttle plays a pivotal role in maintaining cellular NADPH levels. Taken together, these shuttle mechanisms enable cells to maintain redox and energy homeostasis under a wide range of physiological conditions.

**Biosynthesis and Cellular Distribution of GSH**

GSH is the most abundant thiol antioxidant in mammalian cells. It serves as a substrate for H₂O₂ removal by GPxs and itself is oxidized to GSSG (55, 88). The recycling of GSSG to GSH is catalyzed by GR using NADPH as an electron donor. In addition to its antioxidant function, GSH is also involved in modulation of cellular redox signaling (e.g., protein S-glutathionylation), regulation of cell proliferation and cell death, and detoxification of xenobiotics and their metabolites (2, 19, 55).

**GSH biosynthesis**

GSH is a tripeptide and is synthesized from precursor amino acids, l-glutamate, l-cysteine, and glycine, in the cytosol, through two ATP-dependent steps (Fig. 5). In the first step, glutamate reacts with cysteine to form γ-glutamylcysteine under the catalysis of the rate-limiting enzyme, γ-glutamylcysteine ligase (GCL). The GCL enzyme is composed of two functional subunits: catalytic (GCLC) and modifier (GCLM). In the following step, GSH synthetase (GS) catalyzes the formation of GSH by adding glycine to γ-glutamylcysteine (55, 88). Notably, glutamate and cysteine are linked by an unconventional γ-linkage peptide bond, which can be hydrolyzed only by γ-glutamyl transpeptidase (GGT) (2, 55). Since GGT is expressed on the exofacial surface of specific cells (e.g., the liver, lung, vascular endothelium, kidney tubular cells, and biliary epithelial cells) (63), degradation of GSH takes place only in the extracellular space; intracellular GSH is resistant to degradation (2, 55).

The regulation of GSH synthesis is determined by the availability of its constituent amino acids, especially cysteine and glutamate, and the enzymatic activity of GCL. An excellent review by Lu in 2013 systematically summarized the mechanisms involved in modulations of cysteine availability and GCL activity (55). In the context of this review, we discuss recently identified mechanisms regulating cellular GSH levels.

Hypoxia-inducible factor 1α (HIF-1α) is a central transcriptional regulator of cellular metabolism under hypoxic conditions. Ample evidence supports that (pseudo)hypoxia increases cellular GSH levels via both HIF-1α-dependent and HIF-1α-independent mechanisms. Lu et al. reported that the GCLM subunit and the cystine transporter (xCT, encoded by SLC7A11 gene) are transcriptional targets of HIF-1α in triple negative breast cancer cells under hypoxia (53). Treating these cells with chemotherapeutic drugs stimulated the mRNA and protein expression of these two genes and increased intracellular GSH levels through an HIF-1α-dependent mechanism (53). Knockout of prolyl hydroxylase domain-containing protein 2 (PHD2) stabilized HIF-1α protein and activated HIF-1α signaling, which transcriptionally upregulated glutaminase 1 (GLS1) expression leading to a decrease in ROS production and increases in cellular GSH levels, GSH/GSSG, and cell survival in murine periskeletal progenitor cells, suggesting that HIF-1α signaling promotes glutaminolysis to provide glutamate for GSH synthesis (96). Interestingly, HIF-1α-independent regulation of GSH synthesis has also been reported under hypoxia. Recent work showed that hypoxia upregulated xCT SLC7A11 expression and increased intracellular cystine levels and GSH synthesis in multiple types of cancer cells (62, 82). Mechanistically, SLC7A11 upregulation was mediated by activation of the protein kinase RNA-like ER kinase/eukaryotic initiation
factor 2α (eIF2α) branch of the ER stress response but not HIF-1α signaling. Activation of transcription factor eIF2α could transcriptionally upregulate SLC7A11 expression or posttranscriptionally stabilize SLC7A11 mRNA in a cell type-specific manner (62, 82). In addition, p53 can transcriptionally upregulate mitochondrial glutaminase (GLS2) expression in several cancer cells under unstressed and stressed conditions (e.g., ionizing radiation and \( \text{H}_2\text{O}_2 \)) (36). Enhanced expression of GLS2 by p53 activation or by ectopic overexpression promoted glutaminolysis leading to increases in cellular glutamate and GSH levels (36).

The metabolites lactate and fumarate are also regulators of GSH synthesis. For example, blockade of lactate export by inhibition of monocarboxylate transporter 1 increased intracellular lactate levels and decreased cellular \( \gamma \)-glutamylcysteine and GSH levels in human Raji Burkitt lymphoma cells (16). Mechanistically, lactate accumulation inhibited glucose uptake and glycolysis leading to depletion of cellular ATP levels. Since both GSH synthesis enzymes GCL and GS require ATP for activity, depletion of ATP by lactate suppressed activity and consequently GSH synthesis (16).

In addition, chronic accumulation of fumarate by deletion of fumarate hydratase (FH) led to the formation of succinic GSH, a covalent adduct of fumarate and GSH, which correlated with persistent oxidative stress and cellular senescence in renal cells (121). Interestingly, loss of FH also triggered a compensatory rise in GSH levels by upregulation of cystine transport SLC7A11 expression and increases in cystine uptake and glutaminolysis-dependent GSH biosynthesis (121). Furthermore, evidence from diabetic rats and cultured mature adipocytes demonstrated that fumarate as an electrophile can directly react with GSH and cysteine residues in proteins via a Michael addition reaction forming S-(2-succinyl)-cysteine (sulfination), supporting the view that fumarate can irreversibly modify GSH (1, 67). Taken together, these lines of evidence highlight that GSH biosynthesis is influenced by several interrelated mechanisms, including transcriptional, posttranscriptional, and metabolic regulation.

**Cellular distribution of the GSH/GSGG couple**

The GSH/GSSG couple is the principal redox buffer of a cell owing to its high concentration compared with other redox couples (88). Intracellular GSH distributes in different compartments (Fig. 5). The majority of intracellular GSH (>80%) is in the cytosol with an estimated concentration of 1–11 mM; mitochondrial GSH accounts for 10%–15% of the GSH, with its concentration estimated to be 5–11 mM. Five to 10% of total intracellular GSH is present in the nucleus with a concentration of the same or greater than cytosolic GSH; only a small percentage of GSH is in the ER (55, 88). Intracellular GSH is predominantly in its reduced form (>98%). The GSH/GSSG ratio in the cytosol is typically \( >30:1 \) to 100:1 with a redox potential of \(-290 \text{mV}\); this ratio in the mitochondria is estimated to be \( >100:1 \) with a redox potential of \( \leq -300 \text{mV} \). By contrast, this ratio appears to be 1:1 to 3:1 in the ER with a redox potential of \(-175 \) to \(-185 \text{mV} \), which accounts for the relatively oxidizing environment of the ER (9, 25, 75, 88).

It is notable that cytosolic GSH can exchange with other intracellular compartments. This compartmental exchange mechanism is essential for oxidative defense in the mitochondrion since it cannot synthesize GSH (54). GSH is a negatively charged molecule and cannot freely traverse mitochondrial membranes. Thus, the relocalization of cytosolic GSH to mitochondria requires specific carriers (Fig. 5). The AUT-KG carrier (encoded by SLC25A11) and the dicarboxylate transport mechanisms (dicarboxylate carrier, encoded by SLC25A10) are two potential candidates for importing cytosolic GSH to the mitochondria, mainly in the kidney and liver; the tricarboxylate carrier (encoded by SLC25A1) is a potential GSH transporter in the brain and astrocytes (9, 79).

By contrast, some organelles, such as the nucleus, have their own GSH pools, which are independent of cytosolic GSH (88). This interesting phenomenon implies that cells likely preserve nuclear GSH to maintain a reducing environment and to prevent potential oxidative DNA damage. Thus, the distribution of intracellular GSH is organelle specific and exchange among different (but not all) pools is essential for maintenance of GSH homeostasis.

Mammalian cells can continuously secrete GSH and GSSG into the extracellular compartment. In vivo, the liver is the major source of GSH in the circulation (55, 88). GSH levels in human plasma of healthy adults were estimated to be 2–5 \( \mu \text{M} \) and the GSSG concentration was found to be much lower (0.14 \( \mu \text{M} \)) (40, 66, 101). Intriguingly, plasma GSH levels declined in the elderly and in diabetic patients with a corresponding rise in GSSG levels (85), indicating a shift to a more oxidizing state in aging and diabetes. As mentioned above, extracellular GSH can be catabolized only in the extracellular space of certain cell types that express the GGT enzyme (2). GGT hydrolyzes GSH into glutamate and cysteinyl-glycine, which is further catabolized into cysteine and glycine by dipeptidases at the cell surface (2, 102) (Fig. 5). The resulting amino acids can be taken up by cells for intracellular GSH synthesis. Therefore, this extra/intracellular communication mechanism ensures cellular GSH levels are maintained optimally in the steady state.

**Reductive Stress Induced by NAD(P)H and GSH**

As discussed in the Cellular Redox Network and Redox Stress section, NAD(H) can modulate energy metabolism; and NAD(P)H and GSH are indispensable reducing equivalents in response to oxidative stress. Paradoxically, excessive accumulation of cellular NAD(P)H and/or GSH leads to reductive stress and cellular dysfunction.

**NADH and reductive stress**

An excess of NADH levels leads to reductive stress and ultimately ROS production (Fig. 6). Mitochondrial NADH is oxidized to NAD\(^+\) at mitochondrial respiratory complex I (NADH dehydrogenase). Emerging evidence supports that NADH oxidation at complex I is inhibited under hypoxia, which leads to a buildup of NADH and consequent reductive stress. Berney et al. reported that deletion of two [NiFe]-hydrogenases, Hyd2 and Hyd3, increased the NADH/NAD\(^+\) ratio twofold under hypoxic conditions, resulting in reductive stress and cell death in oxygen-obligate mycobacteria (6). Likewise, hypoxia increased cytosolic NADH/NAD\(^+\) (indicated by an increase in lactate/pyruvate) and induced reductive stress, which correlated with ATP depletion and cytotoxicity in primary rat hepatocytes (43). Under hypoxia, accumulation of NADH is believed to provide more electrons for one-electron reduction of oxygen to \( \text{O}_2^{2-} \) (14). Indeed,
increases in cytosolic NADH/NAD⁺ and mitochondrial NAD(P)H levels were coupled with elevated mitochondrial ROS production in hypoxia-challenged bovine coronary artery smooth muscle cells (24). Recently, we reported that hypoxia triggered reductive stress and enhanced mitochondrial ROS generation in primary human lung fibroblasts (72).

In agreement with these in vitro studies, NADH-induced reductive stress and elevated mitochondrial ROS production were also observed in a cardiac ischemia/reperfusion (IR) injury mouse model. During ischemia, high NADH levels triggered a reversal of succinate dehydrogenase (SDH; complex II) activity leading to accumulation of succinate in various tissues, including the heart. After reperfusion, the accumulated succinate was rapidly reoxidized by SDH leading to ROS generation at complex I through a reverse electron transfer. In addition, reductive stress resulting from high NADH is also associated with elevated ROS production under ambient oxygen tensions. For example, addition of exogenous complex I substrates, such as glutamate plus malate, or αKG, significantly augmented NADH levels and mitochondrial membrane potential, which stimulated H₂O₂ production by ~10-fold in isolated rat brain mitochondria (95). Interestingly, this increase in H₂O₂ production was diminished by over 50% when NADH oxidation and mitochondrial respiration were enhanced by subsequent addition of ADP or the respiratory uncoupler carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP). Furthermore, subsequent addition of the complex I inhibitor rotenone entirely blocked NADH oxidation and caused a potentiation in H₂O₂ production after mitochondrial membrane potential was collapsed by addition of FCCP (95), indicating that a high NADH level is crucial for ROS production at complex I.

Likewise, in isolated bovine heart mitochondria, addition of NADH (1–3 μM) promoted electron transfer from reduced flavin to O₂ forming O₂⁻/H₂O₂ at complex I within seconds (100–200 sec) (46). Treating rat L6 myoblasts with the antioxidant N-acetyl-L-cysteine (NAC; 1 mM for 1 h) induced reductive stress by increasing the NADH/NAD⁺ ratio, mitochondrial H₂O₂ levels, and free radical leak (93). In addition, insulin stimulation increased cellular lactate production and lactate/pyruvate (proportional to NADH/NAD⁺), which promoted cellular O₂⁻/H₂O₂ production by NADH-dependent NOX enzymes in cultured 3D rat thoracic aortic smooth muscle cells (110). Pretreatment with pyruvate or OAA significantly mitigated insulin-induced reductive stress in these cells. These cell-free and cell culture studies suggest that a high NADH/NAD⁺ promotes ROS production and induces reductive stress.

The mitochondrial NNT enzyme catalyzes reversible interconversion of the NADH/NAD⁺ and NADPH/NADP⁺ redox couples. Mounting evidence demonstrates that dysfunction of NNT leads to reductive stress. The NNT enzyme has a loss-of-function variant in C57BL/6J mice owing to a spontaneous mutation at the first exon and a multiple exon deletion (exon 7–11) in the NNT gene (99). Compared with NNT wild-type mice (C57BL/6N mice), isolated liver mitochondria from C57BL/6J mice had higher NADH/total NAD(H) and lower NADPH/total NADP(H) on ADP stimulation, which correlated with a reduced rate of removal of exogenous organic peroxides (33, 81).

Similarly, in isolated gastrocnemius muscle fibers of C57BL/6J mice, addition of pyruvate increased NADH production by the PDH complex, which correlated with a twofold elevation in H₂O₂ levels (17). The production of H₂O₂ was further augmented by fivefold when PDH complex flux was enhanced by the combination of pyruvate and carnitine (17). By contrast, H₂O₂ production was not affected in isolated muscle fibers from C57BL/6N mice (functional NNT) when flux from the PDH complex was stimulated by the same substrates (17). These results suggest that NNT loss-of-function leads to reductive stress through increasing NADH accumulation and decreasing NADPH production, and that NNT can integrate with the PDH complex to form a redox circuit regulating H₂O₂ production. In addition, knockdown of NNT increased cellular and mitochondrial NADH/total NAD(H) in human SK-Hep1 cells under basal and ADP-stimulated conditions compared with control shRNA-transfected cells, whereas cellular and mitochondrial NADPH/total NADP(H) was much lower in NNT-silenced cells, which correlated with an increase in mitochondrial ROS generation (33). These findings suggest that NNT loss-of-function blocks the interconversion of NADH to NADPH leading to NADH accumulation and reductive stress.

These observations were further supported by an in vivo study (69). Nickel et al. showed that under pathological cardiac pressure overload induced by transverse aortic constriction, NNT wild-type C57BL/6N mice displayed more severe heart failure and higher mortality compared with C57BL/6J mice lacking functional NNT activity (69). Enhanced failure in the myocardium of wild-type mice coincided with a decline in NADPH levels and an increase in NADH, H₂O₂ production, and oxidative damage (69). These findings suggest that pathological cardiac pressure overload induces NNT reverse functional mode to generate NADH at the expense of NADPH resulting in a high NADH/NAD⁺ and reductive stress, further promoting ROS at complex I leading to oxidative injury and cell death (Fig. 6).

Of note, the NADH/NAD⁺ imbalance-induced reductive stress is a common phenomenon in diabetes and diabetic syndromes. The central hypothesis is that diabetic hyperglycemia causes a pseudohypoxic increase in the NADH/
NAD$^+$ ratio and reductive stress (57, 103). Specifically, during chronic hyperglycemia, NADH production is enhanced through glycolysis and the polyol pathways, whereas NAD$^+$ levels are depleted owing to overactivation of NAD$^+$-consuming enzymes (e.g., poly ADP ribose polymerase [PARP]), together leading to an increase in the NADH/NAD$^+$ ratio and promoting ROS production by mitochondrial respiratory complex I due to NADH overload, eventually resulting in reductive stress (38, 105, 107). For example, using a streptozotocin-induced diabetic rat model, Wu et al. found activation of the polyol pathway and an upregulation of PARP-1 in the lungs of diabetic rats compared with nondiabetic animals, which correlated with increases in the NADH/NAD$^+$ ratio, the activities of mitochondrial respiratory complex I–IV, and cellular ROS production (104), supporting the view that reductive stress occurs in the development of diabetic complications. Taken together, these lines of in vitro and in vivo evidence highlight that excess NADH induces reductive stress and ultimately promotes ROS generation.

**NADPH/GSH and reductive stress**

NADPH and GSH are essential for oxidative stress defense; and NADPH is indispensable for GSH recycling by GR (see the Cellular Redox Network and Redox Stress section). However, excessive levels of cellular GSH and/or NADPH also lead to reductive stress (Fig. 7).

NADPH is a substrate for NOX enzymes to produce H$_2$O$_2$ and O$_2^{**}$ (5). As expected, cardiac-specific overexpression of wild-type NOX4 (WT-NOX4) decreased NADPH/NADP$^+$ and GSH/GSSG, which correlated with enhanced ROS production and cardiac dysfunction in mice under IR challenge (116). By contrast, overexpression of a dominant negative mutant of NOX4 (DN-NOX4; loss of NOX4 activity) increased the ratios of these two redox couples in the myocardium. Paradoxically, elevated ROS levels and cardiac dysfunction were also observed in DN-NOX4 mice under IR challenge, indicating that high NADPH and GSH levels also enhance ROS generation and induce reductive stress by mechanisms yet to be determined (116).

G6PD is the major source of the cytosolic NADPH pool (see the Metabolic Sources and Cellular Distribution of the NAD(H) and NADP(H) Couples section). Overexpression of G6PD increased cellular NADPH levels and upregulated the expression of NOX cofactors, which potentiated ROS production and oxidative damage in mouse pancreatic $\beta$ cells and thymic lymphoma cells (48, 97). By contrast, loss of G6PD activity was found to be beneficial in many disease models by limiting generation of high NADPH levels and reductive stress. For example, G6PD deficiency reduced NADPH levels and significantly inhibited angiotensin II (Ang II)-induced $O_2^{**}$ production and thickening of the medial layer of the aorta (64). Similar effects were observed in pacing-induced heart failure where inhibition of G6PD activity abrogated elevations in NADPH levels and ROS production in failing hearts (28).

Furthermore, mice with cardiac-specific overexpression of a mutated human $\alpha$B-crystallin (R120G mutant) developed protein aggregation cardiomyopathy and exhibited reductive stress in the heart as evidenced by increases in GSH levels, GSH/GSSG, and the activities of GR, G6PD, catalase, and GPx (77). Notably, these pathological alternations and reductive stress were significantly normalized by replacing the wild-type G6PD with a hypomorphic G6PD mutant in the R120G mice (77), suggesting that the G6PD-mediated reductive stress contributes to the development of this disease. Mechanistically, the reductive stress observed in R120G mutant mice was attributed to activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF-2) signaling pathway, which transcriptionally upregulated the mRNA or/and protein expression of key antioxidant enzymes (e.g., GR, G6PD, GPx1, and catalase) and GSH synthetic enzymes (e.g., GCLC and GCLM), leading to increases in the GSH content and GSH/GSSG ratio, and to a decrease in ROS levels in heart tissue (77, 91). Importantly, knockout of NRF2 significantly aborted the upregulated gene expression, normalized reductive stress, and reduced cardiac hypertrophy in R120G mutant mice (41, 78).

Likewise, a lamin C mutation in muscle tissues of Droso- phila or human muscular dystrophy patients led to reductive stress demonstrated by increases in GSH and NADPH levels.
and activation of the NRF-2 pathway (15). Mechanistically, the increase in NADPH levels was contributed by elevated IDH activity but was independent of G6PD and 6PGD activity in this model (15). Unlike under oxidative stress where NRF-2 activation is mediated by oxidative inactivation of its sequester protein Keap-1, its activation under reductive stress was mediated by upregulation of an autophagy adaptor p62/SQSTM1, which also binds Keap-1 and thus enables nuclear translocation of NRF-2 and activation of its target genes (15).

In addition, transgenic mice with cardiac-specific heat shock protein 27 (Hsp27) overexpression developed cardiac hypertrophy and dysfunction, which correlated with increases in GSH levels, GSH/GSSG, and GPx1 activity and with a decrease in total ROS levels in the heart (119). Inhibition of GPx1 activity partially normalized the cardiomyopathy in Hsp27 transgenic mice, suggesting that reductive stress induced by excess GSH levels and GPx1 activity contributes to cardiac dysfunction in this model (119). Furthermore, increases in cellular GSH levels by either supplementing with the thiol-donor NAC or overexpressing GSH synthetic enzyme GCLC or/and GCLM subunit(s) diminished cellular ROS levels and reduced cellular 2GSH/GSSG redox potential by 7–12 mV (117). Paradoxically, this more reducing redox environment correlated with increases in mitochondrial oxidation and cell death, suggesting that elevated GSH levels result in reductive stress and cytotoxicity (117). Taken together, these lines of evidence clearly support that excess NADPH or/and GSH levels induce reductive stress.

**Metabolic Responses to Reductive Stress**

The NAD(H), NADP(H), and GSH/GSSG redox couples are critical regulators of cellular metabolism. Specifically, glycolysis and the TCA cycle produce NADH, which provides electrons for mitochondrial OXPHOS and ATP production (56). NADPH supports the PPP to generate NADPH that is indispensable for reductive biosynthesis of nucleotides, amino acids, and lipids (56). GSH links amino acid metabolism with cellular redox status. Thus, reductive stress induced by altered ratios of these three redox couples affects cellular metabolism and vice versa.

**Metabolic coordination under NAD(P)H-induced reductive stress**

Metabolic adaption to hypoxia is a vital survival mechanism for metazoa. Under hypoxia, cell metabolism shifts away from mitochondrial OXPHOS to glycolysis for energy production, which is primarily mediated by activation of HIF-1α signaling. As mentioned in the Reductive Stress Induced by NAD(P)H and GSH section, hypoxia also induces reductive stress by NADH accumulation. Whether or not there is a link between reductive stress and metabolic reprogramming had not been well understood until recently.

We and others showed that l-2-hydroxyglutarate (L2HG), a reduced metabolite of α-KG by MDH1/2 or LDHA, selectively accumulated as a fundamental response to hypoxia in various primary and cancer cells (39, 72). The accumulation of L2HG levels correlated with increases in cellular NADH/NADH and mitochondrial ROS production indicative of reductive stress under hypoxia (72). Strikingly, increasing cellular L2HG levels by knockdown of L2HG dehydrogenase (the only known enzyme that oxidizes L2HG back to α-KG) decreased mitochondrial oxygen consumption and lactate production, which indicates that L2HG could inhibit both mitochondrial respiration and glycolysis to blunt their production of NADH and to mitigate attendant reductive stress (72).

The mitochondrial NNT enzyme is an important source of mitochondrial NADPH levels (see the Metabolic Sources and Cellular Distribution of the NAD(H) and NADP(H) Couples section). Overexpression of NNT increased NADPH/NADP+ resulting in reductive stress in melanoma cells (23). Intriguingly, NADPH-dependent reductive stress stimulated glutaminolysis to generate α-KG, which was then converted to succinyl-CoA by oxidative decarboxylation in the TCA cycle or to citrate via IDH2-mediated reductive carboxylation (23). By contrast, NNT silencing decreased NADH/NADH and NADPH/NADP+, which correlated with a decline in glutamine catabolism and a rise in the flux of glucose oxidation into the TCA cycle and energy production thereby (23). These results suggest that melanoma cells switch their energy source from glucose to glutamine under conditions of reductive stress.

A very recent study also reported reductive stress and metabolic reprogramming in human SK-Hep1 cells with NNT knockdown (33). Specifically, knockdown of NNT resulted in elevations in cellular and mitochondrial NADH/total NADH and decreases in cellular and mitochondrial NADPH/total NADP+ with a concomitant increase in mitochondrial O2− production, indicating that NNT silencing induces reductive stress in these cells (33). Intriguingly, NNT silencing also promoted mitochondrial membrane hyperpolarization, increased oxygen consumption and ATP production, and diminished lactate production, implying a metabolic shift from glycolysis to mitochondrial OXPHOS to correct the accumulation of NADH in these cells. This metabolic shift led these cells being more vulnerable to the cytotoxic effects of the mitochondrial OXPHOS inhibitor rotenone but more resistant to the glycolysis inhibitor 3-bromopyruvate (33). Moreover, enhanced glutaminolysis and reductive carboxylation were also observed in NNT-silenced cells, leading to accumulation of α-KG and its derivative metabolites (e.g., citrate, fumarate, and malate). Mechanistically, this inhibition of glycolytic activity was attributable to destabilization of HIF-1α protein, possibly through α-KG-dependent PHD enzyme-mediated hydroxylation and enhanced degradation of HIF-1α protein (33).

In addition, primary mouse aortic endothelial cells isolated from C57BL/6J mice consumed less oxygen, had lower GPx activity, and produced more O2− when stimulated by Ang II compared with cells from C57BL/6N mice, suggesting that loss of NNT function impairs mitochondrial function (49). Furthermore, increasing evidence strongly supports that reductive stress observed in C57BL/6J mice lacking functional NNT correlated with systemic metabolic alterations demonstrated by glucose intolerance, reductions in glucose-induced insulin secretion and energy expenditure, and an increase in susceptibility to high-fat diet-induced obesity (17, 20, 21, 33, 68, 80).

Of note, NNT can also operate in a reverse mode to generate NADH from NADPH and NAD+, resulting in elevated NADH/NAD+, reductive stress, and metabolic adaption. For example, in C57BL/6N mice challenged with pressure overload using transverse aortic constriction, NNT operated through its reverse enzymatic mode, which promoted NADH production at the expense of NADPH and its antioxidant
Increased NADH production accelerated mitochondrial respiration by fueling mitochondrial OXPHOS, which combined with the compromised antioxidant capacity of NADPH resulted in increases in mitochondrial ROS production and oxidative damage, and ultimately cardiac dysfunction (69). These findings indicate that cardiomyocytes correct NADH-induced reductive stress by stimulating its oxidation through mitochondrial respiration.

In isolated pancreatic islets of C57BL/6N mice, glucose stimulation increased the NADPH/total NADP(H), which correlated with a reduction in mitochondrial GSH oxidation (86). Interestingly, the increased ratio was caused by a suppression of the reverse operation of NNT enzyme rather than a stimulation of its forward operation since NADH/total NAD(H) was also elevated by the identical challenge. The rise in NAD(P)H levels correlated with enhancement of glucose-stimulated insulin secretion, glycolysis (as demonstrated by elevated levels of G-6-P and F-6-P), and mitochondrial respiration (as demonstrated by increases in glucose oxidation, oxygen consumption, ATP production, and the TCA cycle intermediate metabolites citrate, malate, and fumarate) (86). Collectively, NNT is therefore a key enzyme bridging cell metabolism and reductive stress.

As discussed in the Metabolic Sources and Cellular Distribution of the NAD(H) and NADP(H) Couples section, the malate/aspartate shuttle is a pivotal mechanism for compartmental exchange of NADH and NAD(P)H to maintain high NAD(P)H levels in the cytosol and high NAD(P)H levels in mitochondria. Disruption of this exchange mechanism could perturb NADH/NAD(P)H in both compartments and thus could affect cellular redox homeostasis and energy metabolism (Fig. 8). For example, knockdown of mitochondrial glutamate-oxaloacetate transaminase (GOT2), a key enzyme in the malate/aspartate shuttle, increased cytosolic NADH levels and concurrently reduced mitochondrial NADH levels, which were concomitant with decreased NADPH/NADP(H) and an increase in cellular ROS production in PANC-1 cells (109). GOT2 silencing also significantly inhibited cellular ATP production and cell proliferation, indicating suppression of mitochondrial respiration (109). Interestingly, recovery of GOT2 activity by re-expressing an acetylation-mimetic GOT2 in these cells inhibited cellular ROS production and restored mitochondrial NADH levels, cellular ATP production, and cell proliferation (109).

Moreover, inhibition of the malate/aspartate shuttle with aminooxyacetic acid (AOA, a potent inhibitor of aspartate aminotransferase) augmented cytosolic NADH/NAD(P)H reflected by elevated lactate/pyruvate and glycerol-3-phosphate/DHAP resulting in a more reductive environment in the cytoplasmic compartment of primary porcine aortic smooth muscle cells (3, 4). Notably, AOA treatment also attenuated glucose oxidation and oxygen consumption but increased glycolytic activity and lactate production, indicating a metabolic shift toward glycolysis (3, 4). These results suggest that perturbation of the malate/aspartate shuttle results in cytosolic retention of NADH and reductive stress, decreasing NADH availability in mitochondria and possibly increasing NAD(P)H levels in the cytosol, thereby leading to inhibition of NADH-dependent mitochondrial respiration and enhancement of NAD(H) dependent metabolic shift toward glycolysis.

Such important roles of this shuttle have also been demonstrated in vivo. Cardiac-specific deletion of mitochondrial complex I subunit NDUF54 protein resulted in accumulation of NADH in mitochondria and elevation in NADH/NAD(+) in rodent heart, which correlated with the accelerated development of heart failure induced by pathological pressure overload or isoproterenol (42, 47). Intriguingly, isolated cardiomyocytes from these mice produced lower H(2)O(2) and O2(•-) than cells from wild-type mice (42, 47), indicating that complex I dysfunction leads to reductive stress in the failing heart. Since supraphysiological levels of NADH were reported to inhibit NAD(H)-dependent sirtuin deacetylase (SIRT1–7) (50), accumulated NADH in mitochondria repressed mitochondrial SIRT3 activity leading to hyperacetylation of mitochondrial complex I. Further studies will be needed to understand the observed association between NADH and reductive stress.
proteins (42, 47) (Fig. 8). Specifically, the malate/aspartate shuttle proteins MDH2, α-KG/malate carrier, and GOT2 were found to be hyperacetylated leading to suppression of the transport and oxidation of cytosolic NADH in mitochondria, which correlated with decreases in oxygen consumption and cardiac energetics (manifested by a reduction in phospho-creatine/ATP) (42, 47). All of these pathological and biochemical changes were significantly abrogated by feeding the NADH precursor NAM mononucleotide to mice or over-expressing NAM phosphoribosyltransferase, a rate-limiting enzyme of NAD biosynthesis, in cardiac tissue (42, 47). Therefore, these results support that reductive stress induced by elevated NADH/NAD⁺ impairs mitochondrial function and energy metabolism in the heart.

By contrast, overexpression of human aspartate-glutamate carrier 1 (AGC1, encoded by SLC25A12 gene) enhanced malate/aspartate shuttle activity on glucose stimulation in rat INS-1E β cells as demonstrated by increases in mitochondrial NAD(P)H levels and cellular glutamate levels (83) (Fig. 8). Moreover, AGC1 overexpression also potentiated glucose-induced increases in glucose oxidation, mitochondrial membrane hyperpolarization, ATP production, and insulin secretion but inhibited lactate secretion compared with empty adenoviral vector-transfected cells (83), indicating that elevated NAD(P)H levels in mitochondria promote mitochondrial respiration and energy production. Collectively, these lines of evidence support the views that the malate/aspartate shuttle is essential for carrying electrons from cytosolic NADH to mitochondria for OXPHOS and that disruption of such a shuttle leads to reductive stress and metabolic dysfunction.

**Metabolic coordination under GSH-induced reductive stress**

As discussed in the Biosynthesis and Cellular Distribution of GSH section, glutamate is a precursor amino acid of GSH. Glutamate is also a source of α-KG through glutaminolysis, where glutamine is hydrolyzed into glutamate by GLSs (cytosolic GLS1 and mitochondrial GLS2) followed by glutamate conversion into α-KG by GLUDs. Consequently, enhancing glutaminolysis could increase cellular GSH levels and alter cellular redox status and energy metabolism. For example, overexpression of GLS2 markedly elevated cellular glutamate, GSH, and NADH levels as well as GSH/GSGS in three human cancer cell lines, which correlated with diminution in cellular basal ROS levels, implying reductive stress occurs in these cells (36). Interestingly, GLS2-overexpressing cells exhibited increases in cellular α-KG levels, mitochondrial oxygen consumption, and ATP production, suggesting that mitochondrial OXPHOS and the TCA cycle are enhanced under reductive stress. Importantly, reductive stress and metabolic stimulation were significantly normalized by silencing GLS2 (36).

By contrast, GLS1 but not GLS2 was found to mediate HIF-1α-mediated enhancement of glutaminolysis in murine skeletal muscle cells. Activation of HIF-1α signaling by PHD2 deletion under normoxia enhanced glutamate uptake and up-regulated GLS1 expression leading to enhanced glutaminolysis and increases in cellular GSH levels and in GSH/GSGS, which correlated with upregulation of antioxidant genes (SOD1, SOD2, catalase, GPx1, and GR) and reduction in cellular and mitochondrial ROS production, indicative of reductive stress (96). Interestingly, this reductive stress was accompanied by decreases in oxygen consumption and palmitate β-oxidation and increases in glycolytic activity and glycogen storage in these cells (96), indicating inhibition of mitochondrial function and stimulation of glycolysis and glycogenesis.

Furthermore, a recent study revealed that GSH is required for metabolic integration and reprogramming in murine T cells during inflammation (61). On activation, murine T cells expressed 6–10-fold higher GCLC mRNA than resting T cells, which was accompanied by elevated cellular GSH levels. Activated T cells reprogrammed their metabolism by enhancing fluxes of glutamine into the TCA cycle and of glucose into glycolysis in a c-MYC-dependent manner (61). These metabolic adaptive responses were effectively abolished in T cells with GCLC deletion and recapitulated by exogenous addition of GSH or its precursor NAC (61). Collectively, these findings underscore a close link between GSH-related reductive stress and energy metabolism.

**Concluding Remarks**

The NAD(H), NADP(H), and GSH/GSSG redox couples are cofactors or/and substrates for many redox and metabolic enzymes. A delicate balance between the reduced and oxidized forms within each redox couple is a prerequisite for support of cellular redox homeostasis and energy metabolism. When that balance is lost, an excess in cellular NAD(P)H and GSH levels leads to reductive stress, metabolic stress, and cell dysfunction.

As an emerging concept, reductive stress complicates, but expands our understanding of the cellular redox environment. Traditionally, a reducing environment is thought to be beneficial for cell functions and biological processes since an oxidizing environment can lead to oxidative damage to proteins, lipids, and nucleic acids. Reductive stress highlights the facts that excess reducing equivalents (NAD(P)H and GSH) are also detrimental to cells via many mechanisms, including disruption of signaling functions of ROS, induction of ROS generation, perturbation of cell metabolism, and inhibition of protein disulfide formation. Thus, mammalian cells must maintain a balanced redox environment to avoid both oxidative and reductive damage.

Current knowledge about the underlying mechanisms of reductive stress and its biological consequences as well as how cells respond to reductive stress remains limited. For example, although it is clear that NADH accumulation under hypoxia induces reductive stress, it is uncertain as to (i) how NADH accumulates under hypoxia beside inhibition of its oxidation by mitochondrial respiration; (ii) whether or not NADH accumulation is compartment-specific; (iii) whether or not the two NADH shuttles are involved in redistribution; (iv) whether or not the NNT enzyme is involved in redistribution; (v) whether and how NADH accumulation affects the metabolic fates of glucose, lipids, and glutamine; and (vi) how cells respond to mitigate this insult. The answers to these questions remain largely open and require future experimental efforts.

In addition, the influences of GSH-induced reductive stress on cellular metabolism and vice versa are also open questions. This work summarizes limited information that is available in the literature on how modulation of GSH biosynthesis affects cellular metabolism. Notably, another important mechanism by which GSH could modulate cellular
metabolism is through protein S-glutathionylation. Like phosphorylation, S-glutathionylation is an important post-translational modification mechanism that regulates biological function, structural protein folding, and subcellular localization of a target protein. Proteins can be glutathionylated through both nonenzymatic and enzymatic reactions.

The former type of S-glutathionylation is primarily processed during oxidative stress and is often nonspecific and irreversible (58, 79). ROS oxidize GSH into GSSG, which reacts with cysteinyl residues (-SH) on proteins to form PSSG. Ample evidence demonstrates that metabolic enzymes are susceptible to glutathionylation under oxidative stress. For example, glycolytic enzymes (e.g., GAPDH, pyruvate kinase, aldolase, phosphoglycerate kinase, triose phosphate isomerase), TCA cycle enzymes (i.e., aconitate, KGDH, IDH3, succinyl-CoA transferase), and mitochondrial OXPHOS protein complexes (Complex I–V) can be glutathionylated, which results in activation or inactivation of their enzymatic activities thus modulating cellular energetics (12, 18, 25, 44, 59, 70).

By contrast, enzyme-driven S-glutathionylation is typically specific and reversible, and is highly controlled by fluctuation in local GSH/GSSG pools (58, 79). The glutathione-S-transferase is the major enzyme mediating S-glutathionylation by adding GSH to cysteinyl residues of a protein producing PSSG (98); and Grx1 and Grx2 are the primary enzymes catalyzing the reversible reaction (58). To date, little is known about whether glutathionylation of proteins, particularly metabolic enzymes, can occur under reductive stress (high GSH/GSSG) and how this modification impairs cellular metabolic activities. These research topics deserve future investigation.

Acknowledgments

This work is supported by the National Institutes of Health grants HG007690, HL061795, HL119145, and GM107618 to J.L. We thank Stephanie Tribuna for assistance in preparation of this article and apologize to investigators whose work was not mentioned due to space limits.

References

1. Alderson NL, Wang Y, Blatnik M, Frizzell N, Walla MD, Lyons TJ, Alt N, Carson JA, Nagai R, Thorpe SR, and Baynes JW. S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys 450: 1–8, 2006.
2. Aquilano K, Baldelli S, and Cirillo MR. Glutathione: new roles in redox signaling for an old antioxidant. Front Pharmacol 5: 196, 2014.
3. Barron JT, Gu L, and Parrillo JE. Malate-aspartate shuttle, cytoplasmic NADH redox potential, and energetics in vascular smooth muscle. J Mol Cell Cardiol 30: 1571–1579, 1998.
4. Barron JT, Gu L, and Parrillo JE. NADH/NAD redox state of cytoplasmic glycolytic compartments in vascular smooth muscle. Am J Physiol Heart Circ Physiol 279: H2872–H2878, 2000.
5. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245–313, 2007.
6. Berney M, Greening C, Conrad R, Jacobs WR, Jr., and Cook GM. An obligately aerobic soil bacterium activates fermentative hydrogen production to survive reductive stress during hypoxia. Proc Natl Acad Sci U S A 111: 11479–11484, 2014.
7. Buettner GR. Superoxide dismutase in redox biology: the roles of superoxide and hydrogen peroxide. Anticancer Agents Med Chem 11: 341–346, 2011.
8. Buettner GR, Wagner BA, and Rodgers VG. Quantitative redox biology: an approach to understand the role of reactive species in defining the cellular redox environment. Cell Biochem Biophys 67: 477–483, 2013.
9. Calabrese G, Morgan B, and Riemer J. Mitochondrial glutathionylation: regulation and functions. Antioxid Redox Signal 27: 1162–1177, 2017.
10. Canto C, Menzies KJ, and Auwerx J. NAD(+)-Metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab 22: 31–53, 2015.
11. Cederbaum AI. Alcohol metabolism. Clin Liver Dis 16: 667–685, 2012.
12. Chen CL, Zhang L, Yeh A, Chen CA, Green-Church KB, Zweier JL, and Chen YR. Site-specific S-glutathiolation of mitochondrial NADH ubiquinone reductase. Biochemistry 46: 5754–5765, 2007.
13. Chouchani ET, Pell VR, Gaude A, Aksentijevic D, Sondier SY, Robb EL, Logan A, Nadlochiy SM, Ord EN, Smith AC, Eyassu F, Shirley R, Hu CH, Dare AJ, James AM, Rogatti S, Hartley RC, Eaton S, Costa AS, Brooks PS, Davidson SM, Duchen MR, Saeb-Parsy K, Shat toch MJ, Robinson AJ, Work LM, Frezza C, Krieg T, and Murphy MP. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515: 431–435, 2014.
14. Clanton TL. Hypoxia-induced reactive oxygen species formation in skeletal muscle. J Appl Physiol (1985) 102: 2379–2388, 2007.
15. Dialynas G, Shrestha OK, Ponce JM, Zwerger M, Thiemann DA, Young GH, Moore SA, Yu L, Lammerding J, and Wallrath LL. Myopathic lamin mutations cause reductive stress and activate the nrf2/keap-1 pathway. PLoS Genet 11: e1005231, 2015.
16. Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Lu Y, Dang CV, Kumar KG, Butler AA, Bannister TD, Hooper AT, Unsal-Kacmaz K, Roush WR, and Cleveland JL. Blocking lactate export by inhibiting the M collide target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res 74: 908–920, 2014.
17. Fisher-Wellman KH, Lin CT, Ryan TE, Reese LR, Gilliam LA, Cathey BL, Lark DS, Smith CD, Muoio DM, and Neufer PD. Pyruvate dehydrogenase complex and nicotinamide nucleotide transhydrogenase constitute an energy-consuming redox circuit. Biochem J 467: 271–280, 2015.
18. Fratelli M, Demol H, Puype M, Casagrande (11: 341–346, 2011).
19. Fratelli M, Goodwin LO, Orom UA, Lombardi S, Tonelli PA, and Ghezzi P. Gene expression profiling reveals a signaling role of glutathione in redox regulation. Proc Natl Acad Sci U S A 102: 13998–14003, 2005.
20. Freeman H, Shimomura K, Cox RD, and Ashcroft FM. Nicotinamide nucleotide transhydrogenase: a link between insulin secretion, glucose metabolism and oxidative stress. Biochem Soc Trans 34: 806–810, 2006.

21. Freeman HC, Hugill A, Dear NT, Ashcroft FM, and Cox RD. Deletion of nicotinamide nucleotide transhydrogenase: a new quantitative trait locus accounting for glucose intolerance in C57BL/6j mice. Diabetes 55: 2153–2156, 2006.

22. Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 19: 235–251, 1999.

23. Gameiro PA, Laviolette LA, Kelleher JK, Ilipoulos O, and Stephanopoulos G. Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J Biol Chem 288: 12967–12977, 2013.

24. Gao Q and Wolin MS. Effects of hypoxia on relationships between cytosolic and mitochondrial NAD(P)H redox and superoxide generation in coronary arterial smooth muscle. Am J Physiol Heart Circ Physiol 295: H978–H989, 2008.

25. Garcia J, Han D, Sancheti H, Yap LP, Kaplowitz N, and Cadenas E. Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J Biol Chem 285: 39646–39654, 2010.

26. Giorgio M, Trinei M, Migliaccio E, and Pelicci PG. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol 8: 722–728, 2007.

27. Gores GJ, Flarsheim CE, Dawson TL, Nieminen AL, Herman B, and Lemasters JJ. Swelling, reductive stress, and cell death during chemical hypoxia in hepatocytes. Am J Physiol 257: C347–C354, 1989.

28. Gupte SA, Levine RJ, Gupte RS, Young ME, Lionetti V, Labinsky V, Floyd BC, Ojaimi C, Bellomo M, Wolin MS, and Recchia FA. Glucose-6-phosphate dehydrogenase-derived NADPH fuels superoxide production in the failing heart. J Mol Cell Cardiol 41: 340–349, 2006.

29. Han D, Canali R, Garcia J, Aguilara R, Gallagher TK, and Cadenas E. Sites and mechanisms of acotomy inactivation by peroxynitrite: modulation by citrate and glutathione. Biochimie 87: 11913–11921, 2009.

30. Handy DE and Loscalzo J. Redox Regulation of Mitochondrial Function. Antioxid Redox Signal 16: 1323–1367, 2012.

31. Handy DE and Loscalzo J. Responses to reductive stress in the cardiovascular system. Free Radic Biol Med 109: 114–124, 2017.

32. Handy DE, Lubos E, Yang Y, Galbraith JD, Kelly N, Zhang YY, Leopold JA, and Loscalzo J. Glutathione peroxidase-1 regulates mitochondrial function to modulate redox-dependent cellular responses. J Biol Chem 284: 11913–11921, 2009.

33. Ho HY, Lin YT, Lin G, Wu PR, and Cheng ML. Nicotinamide nucleotide transhydrogenase (NNT) deficiency dysregulates mitochondrial retrograde signaling and impeded proliferation. Redox Biol 12: 916–928, 2017.

34. Holmgren A and Luthman M. Tissue distribution and subcellular localization of bovine thioredoxin determined by radioimmunoassay. Biochemistry 17: 4071–4077, 1978.

35. Houtkooper RH, Canto C, Wanders RJ, and Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31: 194–223, 2010.

36. Hu W, Zhang C, Wu R, Sun Y, Levine A, and Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A 107: 7455–7460, 2010.

37. Hui S, Ghergurovic JM, Morscher RJ, Jang C, Teng X, Lu W, Esparza LA, Reya T, Lé Z, Yanxiang Guo J, White E, and Rabinowitz JD. Glucose feeds the TCA cycle via circulating lactate. Nature 551: 115–118, 2017.

38. Ido Y, Kilo C, and Williamson JR. Cytosolic NADH/NAD+, free radicals, and vascular dysfunction in early diabetes mellitus. Diabetologia 40 Suppl 2: S115–S117, 1997.

39. Intlekofer AM, Dematteo RG, Venneti S, Finley LW, Lu C, Judkins AR, Rustenburg AS, Grnaway PB, Chodera JD, Cross JR, and Thompson CB. Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metab 22: 304–311, 2015.

40. Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, and Sternberg P. Redox state of glutathione in human plasma. Free Radic Biol Med 28: 625–635, 2000.

41. Kannan S, Muthusamy VR, Whitehead KJ, Wang L, Gomes AV, Litwin SE, Kensler TW, Abel ED, Hoidal JR, and Rajasekaran NS. Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy. Cardiovasc Res 100: 63–73, 2013.

42. Karamanlis D, Lee CF, Garcia-Menendez L, Kolwicz SC, Jr., Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, and Tian R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab 18: 239–250, 2013.

43. Khan S and O’Brien PJ. Modulating hypoxia-induced hepatocyte injury by affecting intracellular redox state. Biochim Biophys Acta 1269: 153–161, 1995.

44. Kil IS and Park JW. Regulation of mitochondrial NADP+-dependent isocitrate dehydrogenase activity by glutathionylation. J Biol Chem 280: 10846–10854, 2005.

45. Korge P, Calmettes G, and Weiss JN. Increased reactive oxygen species production during reductive stress: the roles of mitochondrial glutathione and thioredoxin reductases. Biochim Biophys Acta 1847: 514–525, 2015.

46. Kussmaul L and Hirst J. The mechanism of superoxide production by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc Natl Acad Sci U S A 103: 7607–7612, 2006.

47. Lee CW, Chavez JD, Garcia-Menendez L, Choi Y, Roe ND, Chiao YA, Edgar JS, Goo YA, Goodlett DR, Bruce JE, and Tian R. Normalization of NADH to NAD+ redox balance as a therapy for heart failure. Circulation 134: 883–894, 2016.

48. Lee JW, Choi AH, Ham M, Kim JW, Choe SS, Park J, Lee CY, Yoon KH, and Kim JB. G6PD up-regulation promotes pancreatic beta-cell dysfunction. Endocrinology 152: 793–803, 2011.

49. Leskov I, Neville A, Shen X, Purdie S, Kevil CG, Granger DN, and Krzywanski DM. Nicotinamide nucleotide transhydrogenase activity impacts mitochondrial redox balance and the development of hypertension in mice. J Am Soc Hypertens 11: 110–121, 2017.

50. Lin SJ, Ford E, Haigis M, Liszt G, and Guarente L. Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev 18: 12–16, 2004.

51. Lloret A, Fuchsberger T, Giraldo E, and Vina J. Reductive stress: a new concept in Alzheimer’s disease. Curr Alzheimer Res 13: 206–211, 2016.

52. Loscalzo J. Adaptions to hypoxia and redox stress essential concepts confounded by misleading terminology. Circ Res 119: 511–513, 2016.
53. Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen J, Bullen JW, and Semenza GL. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A 112: E4600–E4609, 2015.

54. Lu SC. Glutathione synthesis. Biochim Biophys Acta 1830: 3143–3153, 2013.

55. Mason JE, Starke RD, and Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Oncogene 34: 4211–4218, 2015.

56. Martin L and Gardner LB. Stress-induced inhibition of mitochondrial function with emphasis on cysteine oxidation reactions. Biochim Biophys Acta 1830: 3143–3153, 2013.

57. Luo X, Wu J, Jing S, and Yan LJ. Hyperglycemic stress and carbon stress in diabetic glucotoxicity. Aging Dis 7: 90–110, 2016.

58. Mailloux RJ, Jin X, and Willmore WG. Redox regulation of mitochondrial function with emphasis on cysteine oxido-reduction. Redox Biol 2: 123–139, 2014.

59. Mailloux RJ, McBride SL, and Harper ME. Unearthing the secrets of mitochondrial ROS and glutathione in bioenergetics. Trends Biochem Sci 38: 592–602, 2013.

60. Maiti S, Rajkumar A, Matali L, Bhat A, Ghosh A, Agam G, Kaur S, Bhatt NR, Mukhopadhyay A, Sengupta S, and Chakraborty K. Oxidative homeostasis regulates the response to reductive endoplasmic reticulum stress through translation control. Cell Rep 16: 851–865, 2016.

61. Mak TW, Grusdat M, Duncan GS, Dostert C, Nonnemacher Y, Cox M, Binsfeld C, Hao Z, Brustle A, Itsumi M, Jager C, Chen Y, Pinkenburg O, Camara B, Ollert M, Bindslev-Jensen C, Vasiliiou V, Gorrini C, Lang PA, Lohoff M, Harris IS, Hiller K, and Brenner D. Glutathione primes T cell metabolism for inflammation. Immunity 46: 675–689, 2017.

62. Martin L and Gardner LB. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11. Oncogene 34: 4211–4218, 2015.

63. Mason JE, Starke RD, and Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol 13: 36–40, 2010.

64. Matsui R, Xu SQ, Maitland KA, Hayes A, Leopold JA, Handy DE, Loscalzo J, and Cohen RA. Glucose-6-phosphate dehydrogenase deficiency decreases the vascular response to angiotensin II. Circulation 112: 257–263, 2005.

65. McKenna MC, Waagepetersen HS, Schousboe A, and Sonnewald U. Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochondrial transfer of reducing equivalents: current evidence and pharmacological tools. Biochem Pharmacol 71: 399–407, 2006.

66. Michelet F, Gueguen R, Leroy P, Wellman P, Nicolas A, and Szent G. Blood and plasma glutathione measured in healthy subjects by HPLC: relation to sex, aging, biological variables, and life habits. Clin Chem 41: 1509–1517, 1995.

67. Nagai R, Brock JW, Blatnik M, Baatz JE, Bethard J, Walla MD, Thorpe SR, Baynes JW, and Frizzell N. Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress. J Biol Chem 282: 34219–34228, 2007.

68. Nicholson A, Reifsnnyder PC, Malcolm RD, Lucas CA, MacGregor GR, Zhang W, and Leiter EH. Diet-induced obesity in two C57BL/6 substrains with intact or mutant nicotinamide nucleotide transhydrogenase (Nnt) gene. Obesity (Silver Spring) 18: 1902–1905, 2010.

69. Nickel AG, von Hardenberg A, Hohl M, Loffler JR, Kohlhaas M, Becker J, Reil JC, Kazakov A, Bonnekon J, Stadelmaier M, Puhl SL, Wagner M, Bogeski I, Cortassa S, Kappel R, Pasieka B, Lafontaine M, Lancaster CR, Blacker TS, Hall AR, Duchen MR, Kastner L, Lipp P, Zeller T, Muller C, Knopp A, Laufs U, Bohm M, Hoth M, and Maack C. Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. Cell Metab 22: 472–484, 2015.

70. Nulton-Persson AC, Starke DW, Mieyal JJ, and Szewda LJ. Reversible inactivation of alpha-ketoglutarate dehydrogenase in response to alterations in the mitochondrial glutathione status. Biochemistry 42: 4235–4242, 2003.

71. Ohashi K, Kawai S, and Murata K. Identification and characterization of a human mitochondrial NAD kinase. Nat Commun 3: 1248, 2012.

72. Oldham WM, Clish CB, Yang Y, and Loscalzo J. Hypoxia-mediated increases in L-2-hydroxyglutarate coordinate the metabolic response to reductive stress. Cell Metab 22: 291–303, 2015.

73. Palmieri F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pfugers Arch 447: 689–709, 2004.

74. Paniker NV, Srivastava SK, and Beutler E. Glutathione metabolism of the red cells. Effect of glutathione reductase deficiency on the stimulation of hexose monophosphate shunt under oxidative stress. Biochim Biophys Acta 215: 456–460, 1970.

75. Perez-Torres I, Guarner-Lans V, and Rubio-Ruiz ME. Reductive stress in inflammation-associated diseases and the pro-oxidant effect of antioxidant agents. Int J Mol Sci 18: pii: E2098, 2017.

76. Pollak N, Niere M, and Ziegler M. NAD kinase levels control the NADPH concentration in human cells. J Biol Chem 282: 33562–33571, 2007.

77. Rajasekaran NS, Connell P, Christians ES, Yan LJ, Taylor RP, Oroz A, Zhang XQ, Stevenson TJ, Peshock RM, Leopold JA, Barry WH, Loscalzo J, Odellberg SJ, and Benjamin JJ. Human alpha B-crystallin mutation causes oxido-reductive stress and protein aggregation cardiomyopathy in mice. Cell 130: 427–439, 2007.

78. Rajasekaran NS, Varadaraj S, Khanderao GD, Davidson CJ, Kannan S, Firpo MA, Zweier JL, and Benjamin JJ. Sustained activation of nuclear erythroid 2-related factor 2/antioxidant response element signaling promotes reductive stress in the human mutant protein aggregation cardiomyopathy in mice. Antioxid Redox Signal 14: 957–971, 2011.

79. Ribas V, Garcia-Ruiz C, and Fernandez-Checa JC. Glutathione and mitochondria. Front Pharmacol 5: 151, 2014.

80. Roat R, Rao V, Doliba NM, Matsuinsky FM, Tobias JW, Garcia E, Ahima RS, and Imai Y. Alterations of pancreatic islet structure, metabolism and gene expression in diet-induced obese C57BL/6J mice. PLoS One 9: e86815, 2014.

81. Ronchi JA, Francisco A, Passos LA, Figueira TR, and Castilho RF. The contribution of nicotinamide nucleotide transhydrogenase to peroxide detoxification is dependent on the respiratory state and counterbalanced by other sources of NADPH in liver mitochondria. J Biol Chem 291: 20173–20187, 2016.

82. Roussoph KM, Dubois LJ, Keulers TG, van den Beucken T, Lambin P, Bussink J, van der Kogel AJ, Koritzinsky M, and Wouters BG. PERK/eIF2alpha signaling protects therapy resistant hypoxic cells through induction of glu-
thioglycine synthesis and protection against ROS. *Proc Natl Acad Sci U S A* 110: 4622–4627, 2013.
83. Rubi B, del Arco A, Bartley C, Satrustegui J, and Maechler P. The malate-aspartate NADH shuttle member Arabic1 determines glucose metabolic fate, mitochondrial activity, and insulin secretion in beta cells. *J Biol Chem* 279: 55659–55666, 2004.
84. Rydstrom J. Mitochondrial NADPH, transhydrogenase and disease. *Biochim Biophys Acta* 1757: 721–726, 2006.
85. Samiec PS, Drews-Botsch C, Flagg EW, Kurtz JC, Sternberg P, Jr., Reed RL, and Jones DP. Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes. *Free Radic Biol Med* 24: 699–704, 1998.
86. Santos LR, Muller C, de Souza AH, Takahashi HK, Spiegel P, Sweet IR, Chae H, Mulder H, and Jonas JC. NNT reverse mode of operation mediates glucose control of mitochondrial NADPH and glutathione redox state in mouse pancreatic beta-cells. *Mol Metab* 6: 535–547, 2017.
87. Sarsour EH, Kumar MG, Chaudhuri L, Kalen AL, and Goswami PC. Redox control of the cell cycle in health and disease. *Antioxid Redox Signal* 11: 2985–3011, 2009.
88. Schafer FQ and Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic Biol Med* 30: 1191–1212, 2001.
89. Schafer FQ and Buettner GR. Redox state and redox environment in biology. In: *Signal Transduction by Reactive Oxygen and Nitrogen Species: Pathways and Chemical Principles*, edited by Forman HJ, Fukuto JM, and Torres M. Dordrecht, Netherlands: Kluwer Academic Publishers, 2003, pp. 1–15.
90. Schieber M and Chandel NS. ROS function in redox signaling and oxidative stress. *Curr Biol* 24: R453–R462, 2014.
91. Shanmugam G, Narasimhan M, Tamowski S, Darley-Usmar V, and Rajasekaran NS. Constitutive activation of Nrf2 induces a stable reductive state in the mouse myocardium. *Redox Biol* 12: 937–945, 2017.
92. Shen D, Dalton TP, Nebert DW, and Shertzer HG. Glutathione redox state regulates mitochondrial reactive oxygen production. *J Biol Chem* 280: 25305–25312, 2005.
93. Singh F, Charles AL, Schlagowski AI, Bouitbir J, Bonifacio A, Pigaud F, Krahenbuhl S, Geny B, and Zoll J. Reductive stress impairs myoblasts mitochondrial function and triggers mitochondrial hormesis. *Biochim Biophys Acta* 1853: 1574–1585, 2015.
94. Sonveaux P, Vegran F, Schroeder T, Wergn MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, and Dewhirst MW. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. *J Clin Invest* 118: 3930–3942, 2008.
95. Starkov AA and Fiskum G. Regulation of brain mitochondrial H2O2 production by membrane potential and NAD(P)H redox state. *J Neurochem* 86: 1101–1107, 2003.
96. Stegen S, van Gastel N, Eelen G, Ghesquiere B, D’Anna F, Thienpont B, Goveia J, Torrekens S, Van Looveren R, Luyten FP, Maxwell PH, Wieloch B, Lambrechts D, Fendt SM, Carmeliet P, and Carmeliet G. HIF-1alpha induces a stable reductive state in the mouse myocardium. *Diabetes* 54: 721–726, 2005.
97. Tome ME, Johnson DB, Samulitis BK, Dor RT, and Briehl MM. Glucose 6-phosphate dehydrogenase overexpression models glucose deprivation and sensitizes lymphoma cells to apoptosis. *Antioxid Redox Signal* 8: 1315–1327, 2006.
98. Townsend DM. S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. *Mol Interv* 7: 313–324, 2007.
99. Toyoe AA, Lippiat JD, Proks P, Shimomura K, Bentley L, Hugill A, Mijat V, Goldsworthy M, Moir L, Haynes A, Quarterman J, Freeman HC, Ashcroft FM, and Cox RD. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. *Diabetologia* 48: 675–686, 2005.
100. Trotter EW and Grant CM. Thioredoxins are required for protection against a reductive stress in the yeast Saccharomyces cerevisiae. *Mol Microbiol* 46: 869–878, 2002.
101. Wang X, Chi D, Song D, Su G, Li L, and Shao L. Quantification of glutathione in plasma samples by HPLC using 4-fluoro-7-nitrobenzofurazan as a fluorescent labeling reagent. *J Chromatogr Sci* 50: 119–122, 2012.
102. Whitleff JB. Gamma glutamyl transferase. *Crit Rev Clin Lab Sci* 38: 263–355, 2001.
103. Williamson JR, Chang K, Frangos M, Hasen KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, and Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. *Diabetes* 42: 801–813, 1993.
104. Wu J, Jin Z, and Yan LJ. Redox imbalance and mitochondrial abnormalities in the diabetic lung. *Redox Biol* 11: 51–59, 2017.
105. Wu J, Jin Z, Zheng H, and Yan LJ. Sources and implications of NADH/NAD(+) redox imbalance in diabetes and its complications. *Diabetes Metab Syndr* 9: 145–153, 2016.
106. Xiao W, Wang RS, Handy DE, and Loscalzo J. NAD(H) and NADP(H) redox couples and cellular energy metabolism. *Antioxid Redox Signal* 28: 251–272, 2018.
107. Yan LJ. Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. *J Diabetes Res* 2014: 137919, 2014.
108. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, de Cabo R, Sauve AA, and Sinclair DA. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. *Cell* 130: 1095–1107, 2007.
109. Yang H, Zhou L, Shi Q, Zhao Y, Lin H, Zhang M, Zhao S, Yang Y, Ling ZQ, Guan KL, Xiong Y, and Ye D. SIRT3-dependent GOT2 acetylation status affects the malate-aspartate shuttle activity and pancreatic tumor growth. *EMBO J* 34: 1110–1125, 2015.
110. Yang M and Kahn AM. Insulin-stimulated NADH/NAD+ redox state increases NADP(H) oxidase activity in cultured rat vascular smooth muscle cells. *Am J Hypertens* 19: 587–592, 2006.
111. Yang M and Vousden KH. Serine and one-carbon metabolism in cancer. *Nat Rev Cancer* 16: 650–662, 2016.
112. Yang Y and Sauve AA. NAD+ metabolism: bioenergetics, signaling and manipulation for therapy. *Biochim Biophys Acta* 1864: 1787–1800, 2016.
113. Yang Y, Song Y, and Loscalzo J. Regulation of the protein disulfide proteome by mitochondria in mammalian cells. *Proc Natl Acad Sci U S A* 104: 10813–10817, 2007.
114. Ying W. NAD+ and NADH in cellular functions and cell death. *Front Biosci* 11: 3129–3148, 2006.
115. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. *Antioxid Redox Signal* 10: 179–206, 2008.
REDDUCTIVE STRESS AND CELLULAR METABOLISM

Abbreviations Used

\( \alpha-KG \) = \( \alpha \)-ketoglutarate

6PGD = 6-phosphogluconate dehydrogenase

AGC1 = aspartate-glutamate carrier 1

Ang II = angiotensin II

AOA = aminooxyacetic acid

DHAP = dihydroxyacetone phosphate

cIF2\( \alpha \) = eukaryotic initiation factor 2\( \alpha \)

ER = endoplasmic reticulum

F6P = fructose-6-phosphate

FH = fumarate hydratase

FTHFDH = 10-formyl-tetrahydrofolate dehydrogenase

G-3-P = glyceraldehyde-3-phosphate

G-6-P = glucose-6-phosphate

G6PD = glucose-6-phosphate dehydrogenase

GAPDH = glyceraldehyde-3-phosphate dehydrogenase

GCL = \( \gamma \)-glutamylcysteine ligase

GGT = \( \gamma \)-glutamyl transpeptidase

GLS = glutaminase

GLUD = glutamate dehydrogenase

GOT = glutamate-oxaloacetate transaminase

GPDH = glycerol-3-phosphate dehydrogenase

GPx = glutathione peroxidase

GR = glutathione reductase

Gx = glutaredoxin

GS = GSH synthetase

GSH = glutathione

GSSG = GSH disulfide

H2O2 = hydrogen peroxide

HIF-1\( \alpha \) = hypoxia-inducible factor 1\( \alpha \)

Hsp27 = heat shock protein 27

IDH = isocitrate dehydrogenase

IR = ischemia/reperfusion

KGDH = \( \alpha \)-ketoglutarate dehydrogenase

LDH = lactate dehydrogenase

L2HG = L-2-hydroxyglutarate

MDH2 = malate dehydrogenase 2

ME = malic enzyme

MTHFD = methylene-tetrahydrofolate dehydrogenase

NAC = N-acetyl-L-cysteine

NAD\( ^+ \) = nicotinamide adenine dinucleotide

NADH = reduced NAD\( ^+ \)

NADK = NAD\( ^+ \) kinase

NADP\( ^+ \) = phosphorylated NAD\( ^+ \)

NADPH = reduced NADP\( ^+ \)

NAM = nicotinamide

NNT = nicotinamide nucleotide transhydrogenase

NR = nicotinamide riboside

NOX = NAD(P)H oxidase

NRF2 = nuclear factor (erythroid-derived 2)-like 2

O2\( ^{+} \) = superoxide anion

OAA = oxaloacetate

OXPHOS = oxidative phosphorylation

PDH = pyruvate dehydrogenase

PHD2 = prolyl hydroxylase domain-containing protein 2

PPP = pentose phosphate pathway

Prx = peroxiredoxin

PSSG = protein-glutathione disulfide

ReBC = redox buffer capacity

RNS = reactive nitrogen species

ROS = reactive oxygen species

SDH = succinate dehydrogenase

SIRT = sirtuin deacetylase

SOD = superoxide dismutase

TCA = tricarboxylic acid

THF = tetrahydrofolate

TR = thioredoxin reductase

Trx = thioredoxin

xCT = cystine transporter

Date of first submission to ARS Central, May 6, 2019; date of acceptance, June 19, 2019.